Clovis Oncology Inc (CLVS)

36.10
1.00 2.80
NASDAQ : Health Care
Prev Close 37.14
Open 36.88
Day Low/High 36.06 / 37.49
52 Wk Low/High 11.57 / 116.75
Volume 1.74M
Avg Volume 2.61M
Exchange NASDAQ
Shares Outstanding 38.50M
Market Cap 1.48B
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.

Here's Why Shares of Clovis Oncology Are Higher Wednesday

Here's Why Shares of Clovis Oncology Are Higher Wednesday

Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.

Clovis Oncology Charts Suggest Aggressive Buying

Clovis Oncology Charts Suggest Aggressive Buying

The technical signs indicate the stock's price and volume are going up without a dip.

Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades

Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades

Clovis Oncology's (CLVS) stock rating was lifted to 'outperform' at Credit Suisse on takeover talk.

Morning Movers: MYL, XOM, MSFT, GIS, CLVS

Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.

Analysts' Actions -- Clovis, Altria, Sketchers, Wells Fargo and More

Analysts' Actions -- Clovis, Altria, Sketchers, Wells Fargo and More

Here are Wednesday's top research calls, including an upgrade for Clovis Oncology, downgrades for Sketchers USA and Wells Fargo and new coverage for Altria.

Here's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today

Here's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today

Gilead Sciences (GILD) said at the Wells Fargo Conference on Thursday that it is considering investing in a PARP inhibitor like Clovis Oncology's (CLVS) rucaparib.

Here's a Reason Why Clovis Oncology (CLVS) Stock Is Gaining Today

Here's a Reason Why Clovis Oncology (CLVS) Stock Is Gaining Today

Clovis Oncology (CLVS) agreed with Pfizer (PFE) to defer payments for its rucaparib ovarian cancer drug late Tuesday.

'Mad Money' Lightning Round: I Can't Recommend Gilead

'Mad Money' Lightning Round: I Can't Recommend Gilead

Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.

7 Stocks Trading on Big Volume -- and What to Do With Them Now

7 Stocks Trading on Big Volume -- and What to Do With Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

CLVS Crosses Above Average Analyst Target

CLVS Crosses Above Average Analyst Target

In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $21.17, changing hands for $23.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Here's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today

Here's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today

The FDA granted accelerated approval for Clovis Oncology's (CLVS) rucaparib drug.

Clovis Oncology Announces Q2 2016 Operating Results And Corporate Update

Clovis Oncology Announces Q2 2016 Operating Results And Corporate Update

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce Second Quarter 2016 Financial Results And Host Webcast Conference Call On August 8

Clovis Oncology To Announce Second Quarter 2016 Financial Results And Host Webcast Conference Call On August 8

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Clovis Oncology Presents Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting

Clovis Oncology Presents Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting

Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in...

Clovis Oncology Announces Data Presentations At 2016 ASCO Annual Meeting

Clovis Oncology Announces Data Presentations At 2016 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced its presence at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated results from clinical studies of rucaparib.

Clovis Oncology Becomes Oversold (CLVS)

Clovis Oncology Becomes Oversold (CLVS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

The Shuman Law Firm Investigates Clovis Oncology, Inc.

The Shuman Law Firm Investigates Clovis Oncology, Inc.

The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Clovis Oncology, Inc.

Clovis Oncology Announces Q1 2016 Operating Results And Corporate Update

Clovis Oncology Announces Q1 2016 Operating Results And Corporate Update

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter ended March 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce First Quarter 2016 Financial Results And Host Webcast Conference Call On May 5

Clovis Oncology To Announce First Quarter 2016 Financial Results And Host Webcast Conference Call On May 5

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.

Why Clovis Oncology (CLVS) Stock is Tumbling Today

Why Clovis Oncology (CLVS) Stock is Tumbling Today

Clovis Oncology (CLVS) stock is dipping on Wednesday as an FDA advisory committee voted against approving the company's lung cancer drug rociletinib yesterday.

Clovis Lung Cancer Drug Trashed at FDA Panel, CEO Exit Next?

Clovis Lung Cancer Drug Trashed at FDA Panel, CEO Exit Next?

An FDA advisory committee delivers a brutal beatdown of Clovis' lung cancer drug rociletinib. It could cost Clovis' CEO his job.

Trading Of Clovis Oncology, Inc. Common Stock Halted

Trading Of Clovis Oncology, Inc. Common Stock Halted

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company's common stock.

Why Clovis Oncology (CLVS) Stock is Dropping Today

Why Clovis Oncology (CLVS) Stock is Dropping Today

Clovis Oncology (CLVS) stock is continuing to slide on Monday after the FDA questioned its lung cancer drug Friday. An advisory panel is slated to vote on the drug tomorrow.